Posted by Michael Wonder on 24 Jul 2025
Clearside Biomedical announces approval of Xipere suprachoroidal treatment for uveitic macular oedema in Canada
23 July 2025 - Clearside Biomedical announced today that Health Canada has granted approval for Xipere (triamcinolone acetonide injectable suspension) for suprachoroidal use in the treatment of uveitic macular oedema.
Xipere is approved for use in the US, Canada, Australia, and Singapore and under regulatory review in China.
